Skip to content

Low Intensity Aerobic Exercise and Active Exercises in Cancer Patients Receiving Palliative Care

Comparison of Low Intensity Aerobic Exercise and Active Exercises on Cancer Related Fatigue in Cancer Patients Receiving Palliative Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05059990
Enrollment
22
Registered
2021-09-28
Start date
2021-10-10
Completion date
2021-12-30
Last updated
2022-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Low intensity Aerobic Exercise, ROM Exercise, Palliative Care

Brief summary

To compare the effect of low intensity aerobic exercise and active ROM exercises on cancer related fatigue and its associated symptoms and quality of life in cancer patients receiving palliative care.

Interventions

OTHERLow Intensity Aerobic Exercises Group

Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session

OTHERActive Exercises Group

Intervention Upper and lower limb ROM & stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session

Sponsors

Riphah International University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ability to give written consent. * Diagnosed advance cancer specifically gastrointestinal tract (GIT) cancer, Lung cancer and Breast cancer etc. (stage 2 and 3). * Intensity of fatigue ≥4 out of 10 on fatigue Numerical Rating Scale in first visit observation * Survival expectancy more than one month, * Functional status allowing the participants to participate in the proposed therapy.

Exclusion criteria

* Anemia (Hb ≤ 8g/dl), * Existence of other comorbidities causing fatigue (i.e. Parkinson's, Multiple sclerosis, Heart failure), * Infection requiring antibodies * bone metastases, * thrombocytopenia (\<50×109/l), * myocardial infarction within the past three months * uncontrolled hypertension (diastolic pressure \>95 mm Hg).

Design outcomes

Primary

MeasureTime frameDescription
Fatigue Numeric Rating Scale4th WeekThe fatigue numeric rating scale (NRS) is a single-item measure assessing severity of fatigue. We will use this in our study to measure the severity of cancer related fatigue in oncology patients receiving palliative care. The fatigue NRS is a patient- administered, single- item, 11- point horizontal scale anchored at 0 and 10, with 0 representing 'no fatigue' and 10 representing 'as bad as participant can imagine'. Changes from the baseline to 4 week
Karnofsky Performance Status4 WeekThe Karnofsky Performance Scale Index is an assessment tool for functional impairment. It can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. It is a standard way of measuring the ability of cancer patients to perform ordinary tasks. The Karnofsky Performance Status scores range from 0 to 100. A higher score means the patient is better able to carry out daily activities. Changes from the baseline to 4 week
Edmonton Symptom Assessment Scale (ESAS)4 weekThis tool is designed to assess nine common symptoms experienced by cancer patients, including pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, shortness of breath. The severity for each symptom ranges from 0 to 10 where 0 means absence of symptom to 10 being the worst possible severity. Changes from the baseline to 4 week
Brief Fatigue Inventory (BFI):4 weekIt is used to rapidly assess the severity and impact of cancer-related fatigue on daily functioning in past 24 hours, which requires a very short time to fill and the global fatigue scoring can be obtained by averaging all the 4 items on the BFI. Changes from the baseline to 4 week

Secondary

MeasureTime frameDescription
Quality of life questionnaire for cancer patients treated with anti-cancer drugs (QOL-ACD):4 weekQuality of Life Anti-Cancer Drugs (QOL-ACD) is a Quality-of-life measurement tool for patients undergoing chemotherapy it has 22 items, divided into these categories: daily activities, physical condition, social activities, mental and psychological status. Scaling of items is from 5 to 1(5 being worst and 1 being good) for 21 items, and a five-point face scale for 1 item. Changes from the baseline to 4 week

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026